Escalating automation presents enormous possibilities for Pharmaceutical brands because they seek to create drugs far more rapidly, successfully and cost-properly. But extra automation inevitably implies extra complexity and an increasing chance of failure and non-conformance in close merchandise.The FDA includes a right to overview and replica all